Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127200711 | 12720071 | 1 | I | 2013 | 20160822 | 20160907 | 20160907 | PER | US-ASTRAZENECA-2016SE90751 | ASTRAZENECA | 57.00 | YR | F | Y | 94.30000 | KG | 20160907 | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127200711 | 12720071 | 1 | PS | FARXIGA | DAPAGLIFLOZIN PROPANEDIOL | 1 | Oral | 202293 | 5 | MG | TABLET | QD | |||||||
| 127200711 | 12720071 | 2 | SS | FARXIGA | DAPAGLIFLOZIN PROPANEDIOL | 1 | Oral | 202293 | 2 | DF | TABLET | QD | |||||||
| 127200711 | 12720071 | 3 | SS | LISINOPRIL. | LISINOPRIL | 1 | Oral | 73060 | MG | 0 | 20 | MG | TABLET | QD | |||||
| 127200711 | 12720071 | 4 | SS | METOPROLOL SUCCINATE. | METOPROLOL SUCCINATE | 1 | Oral | 182650 | MG | 0 | 50 | MG | MODIFIED-RELEASE TABLET | QD | |||||
| 127200711 | 12720071 | 5 | C | LIPITOR | ATORVASTATIN CALCIUM | 1 | Oral | 0 | 80 | MG | QD | ||||||||
| 127200711 | 12720071 | 6 | C | ZETIA | EZETIMIBE | 1 | Oral | 0 | 10 | MG | QD | ||||||||
| 127200711 | 12720071 | 7 | C | SPIROLACTONE | SPIRONOLACTONE | 1 | Oral | 0 | 25 | MG | QD | ||||||||
| 127200711 | 12720071 | 8 | C | NORCO | ACETAMINOPHENHYDROCODONE BITARTRATE | 1 | Oral | 0 | 5 | MG | QD | ||||||||
| 127200711 | 12720071 | 9 | C | FLEXERIL | CYCLOBENZAPRINE HYDROCHLORIDE | 1 | Oral | 0 | 5 | MG | QD | ||||||||
| 127200711 | 12720071 | 10 | C | NABUMETONE. | NABUMETONE | 1 | Oral | 0 | 500 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127200711 | 12720071 | 1 | Type 2 diabetes mellitus |
| 127200711 | 12720071 | 2 | Type 2 diabetes mellitus |
| 127200711 | 12720071 | 3 | Blood pressure measurement |
| 127200711 | 12720071 | 4 | Hypertension |
| 127200711 | 12720071 | 5 | Blood cholesterol abnormal |
| 127200711 | 12720071 | 6 | Blood cholesterol abnormal |
| 127200711 | 12720071 | 7 | Hypertension |
| 127200711 | 12720071 | 8 | Pain |
| 127200711 | 12720071 | 9 | Pain |
| 127200711 | 12720071 | 10 | Pain |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127200711 | 12720071 | Blood glucose fluctuation | |
| 127200711 | 12720071 | Malaise | |
| 127200711 | 12720071 | Memory impairment | |
| 127200711 | 12720071 | Off label use | |
| 127200711 | 12720071 | Weight decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127200711 | 12720071 | 1 | 201604 | 0 | ||
| 127200711 | 12720071 | 2 | 201606 | 201608 | 0 | |
| 127200711 | 12720071 | 3 | 2006 | 0 | ||
| 127200711 | 12720071 | 4 | 2006 | 0 | ||
| 127200711 | 12720071 | 5 | 2006 | 0 | ||
| 127200711 | 12720071 | 6 | 2006 | 0 | ||
| 127200711 | 12720071 | 7 | 2006 | 0 | ||
| 127200711 | 12720071 | 8 | 2004 | 0 | ||
| 127200711 | 12720071 | 9 | 2004 | 0 | ||
| 127200711 | 12720071 | 10 | 2004 | 0 |